Ustekinumab was deemed safe to progress to efficacy studies at doses used to treat psoriasis in adults with T1D. A 90 mg maintenance dosing schedule reduced proinsulin-specific IFN-γ and IL-17A-producing T cells. Further studies are warranted to determine whether Ustekinumab can prevent C-peptide AUC decline and induce a clinical response. The gene discussed is IFNG; the disease is psoriasis.